SPOTLIGHT -
EP. 1: Introduction: Upfront Treatment in Patients With CLL
EP. 2: First-Line Treatment Selection in CLL
EP. 3: Safety and Efficacy of Obinutuzumab in CLL
EP. 4: Optimizing Treatment With Ibrutinib in High-Risk CLL
EP. 5: Role of Transplantation in High-Risk CLL
EP. 6: Maintenance Therapy in Chronic Lymphocytic Leukemia
EP. 7: Strategies for Managing Immune Thrombocytopenia in CLL
EP. 8: Novel Treatment Approaches to Relapsed/Refractory CLL
EP. 9: Role of NOTCH1 Mutations in CLL
EP. 10: Assessing Response With Novel Agents in CLL
EP. 11: Indolent Non-Hodgkin's Lymphoma Treatment Selection
EP. 12: Translating Novel CLL Therapies to Other Types of NHL
EP. 13: Improving Outcomes in Mantle Cell Lymphoma
EP. 14: Utility of MRD in Mantle Cell Lymphoma
EP. 15: Strategies for Treating Myc-Positive DLBCL
EP. 16: Treatments and Phenotypes in DLBCL
EP. 17: Closing Thoughts: A Cure in Sight for CLL?
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC
